Wills Eye

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wills Eye sits in the top decile of US sponsors by registered trial count (#338 of 15,742 sponsors by registered trial count).

59 total trials 2 currently recruiting 52 completed early-phase tilt top decile by trial count

Wills Eye: 59 sponsored US clinical trials, 2 recruiting.

Wills Eye sponsors 59 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 52 completed. 5 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glaucoma, with 5 trials.

Top-decile sponsor footprint

Wills Eye ranks in the top decile of sponsors by registered trial count (#338 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 72/100

52 of 56 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

What is open in the Wills Eye pipeline

2 recruiting of 59 indexed (3% open); 52 completed (88%).

Phase mix: 5 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Glaucoma (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wills Eye: open-pipeline peers nationwide

Peers matched on 59 registered trials and 3% open enrollment, not the therapeutic-area sidebar.

Wills Eye sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20%25% Total trials Recruiting share Wills EyeClinical Nutrition Research Center, Illinois Institute of TechnologyUnited States Army Research Institute of Environmental MedicineUniversity of GeorgiaHenry M. Jackson Foundation for the Advancement of Military MedicineSCRI Development InnovationsBiotronikCharles Drew University of Medicine and ScienceKyntra Bio
Wills Eye sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wills Eye sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 59 trials (± recruiting share)

Sponsors near 3% open enrollment (± trial volume)

What to do with this Wills Eye page

59 registered trials is a research-attention snapshot, not an endorsement of Wills Eye or any single study.

  • 2 of Wills Eye's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Glaucoma is the condition Wills Eye studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glaucoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wills Eye pipeline card: 59 registered trials from official public datasets.Report a data error.